

HITS and eMolecules Forge Strategic Alliance to Revolutionize Global Drug Discovery

Seoul, South Korea - April 29, 2025

HITS, a leading AI-powered drug discovery platform, has announced a strategic partnership with eMolecules, a global provider of chemical building blocks and synthesis services for the pharmaceutical industry. This collaboration is set to accelerate early-stage drug discovery and development on a global scale by combining HITS' cutting-edge AI technology with eMolecules' extensive chemical sourcing and synthesis capabilities.

This MOU also marks a strategic step for HITS to expand global partnerships aimed at penetrating international pharmaceutical markets.

The Memorandum of Understanding (MOU) was signed at HITS' headquarters in Seoul by Woo Yeon Kim, CEO of HITS, and Deren Koseoglu, Vice President of Global Business at eMolecules. This partnership aims to streamline workflows, enhance efficiency, and reduce timelines in the drug discovery process.

HITS recently unveiled its groundbreaking Hyper Screening X service at the Drug Discovery Conference in San Diego. Powered by deep learning technology and a 7-trillion-compound virtual library, Hyper Screening X identifies synthesizable lead molecules with unprecedented speed and precision. This innovation complements HITS' flagship SaaS platform, HyperLab, which leverages generative AI to improve hit discovery success rates and cut development timelines by up to 90%.

HITS is leveraging this momentum through its recent participation in global industry events such as AACR and DDC and is now accelerating outreach to pharmaceutical companies worldwide.

"HITS is committed to transforming early-stage drug discovery through AI," said Wooyeon Kim, CEO of HITS. "Our partnership with eMolecules will provide researchers worldwide with faster access to high-potential molecules, paving the way for a new paradigm in AI-driven drug development."

eMolecules brings its expertise as a leader in chemical compound management and synthesis. Following its acquisition of Synple Chem AG in 2024, the company offers an integrated solution for chemical sourcing and synthesis execution. "This collaboration represents more than just technical integration," said Deren Koseoglu, VP of Global Business at eMolecules. "It's a strategic

PRESS RELEASE

milestone that aligns with our shared mission of advancing global drug discovery while expanding our footprint in Asia.”

With over 300 pharmaceutical companies, research institutes, and universities already utilizing HyperLab, HITS is poised to launch an expanded version of Hyper Screening X in Q3 2025. This enhanced service will deliver an end-to-end drug discovery experience—from molecule generation to synthesis and final delivery.

About HITS

Founded in Seoul, Korea, HITS is a leading innovator in AI-driven drug discovery. Its flagship SaaS platform, HyperLab, leverages proprietary generative AI models to accelerate the design and screening of drug-like molecules. HyperLab is used by over 300 organizations worldwide—including major pharmaceutical companies, academic institutions, and government research institutes—for hit identification and early-stage R&D. Key users include the Korea Research Institute of Chemical Technology (KRICT) and the MD Anderson Cancer Center in the United States. In 2025, HITS launched Hyper Screening X, a next-generation screening service that integrates deep learning and ultra-large-scale chemical libraries, offering a one-stop solution from virtual screening to synthesis and delivery.

About eMolecules

Founded in 2005 and headquartered in San Diego, eMolecules specializes in chemical compound sourcing and synthesis services. With a database of over 83 million compounds and advanced supply chain management capabilities, the company empowers researchers globally to accelerate drug discovery. In 2024, eMolecules expanded its capabilities by acquiring Synple Chem AG, a Swiss company specializing in automated chemical synthesis systems. eMolecules continues to empower pharmaceutical, biotechnology, and academic researchers worldwide by removing inefficiencies in chemical sourcing and accelerating innovation in drug discovery.

For media inquiries

eMolecules

Harrie Elzinga

Sales Enablement Director

marketing@emolecules.com